JMP Securities Reiterates Market Outperform on Crinetics Pharmaceuticals, Maintains $43 Price Target
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Jonathan Wolleben reiterated a Market Outperform rating on Crinetics Pharmaceuticals (NASDAQ:CRNX) and maintained a $43 price target.
June 15, 2023 | 12:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities reiterated a Market Outperform rating on Crinetics Pharmaceuticals and maintained a $43 price target.
The reiteration of the Market Outperform rating and maintenance of the $43 price target by JMP Securities analyst Jonathan Wolleben indicates a positive outlook for Crinetics Pharmaceuticals. This news is likely to have a positive impact on the stock price in the short term as it reaffirms the analyst's confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100